CV Sciences (CVSI) Capital Expenditures Growth (3y) (2016 - 2021)
CV Sciences (CVSI) Capital Expenditures Growth (3y) (2016 - 2021) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.42 Bn | 87.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.89 Bn | 32.15 Bn | 1.97 Bn | 6.52% |
| 3 | Zoetis | 32.44 Bn | 30.50 Bn | 1.62 Bn | 232.22% |
| 4 | Takeda Pharmaceutical | 27.55 Bn | 23.49 Bn | 4.39 Bn | 1.64% |
| 5 | United Therapeutics | 23.13 Bn | 20.98 Bn | 648.10 Mn | 75.58% |
| 6 | RedHill Biopharma | 21.17 Bn | 21.17 Bn | - | - |
| 7 | Viatris | 20.33 Bn | 18.53 Bn | 1.16 Bn | -5.84% |
| 8 | Neurocrine Biosciences | 17.77 Bn | 16.45 Bn | 800.70 Mn | 32.64% |
| 9 | Elanco Animal Health | 12.63 Bn | 12.20 Bn | 785.00 Mn | 28.56% |
| 10 | CV Sciences | 4.11 Mn | 3.80 Mn | 1.56 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2021 | -36.70% |
| Dec 31, 2020 | 22.26% |
| Jun 30, 2020 | 306.32% |
| Sep 30, 2019 | -54.46% |
| Dec 31, 2018 | 235.99% |
| Jun 30, 2018 | -122.59% |
| Mar 31, 2018 | 22.70% |
| Dec 31, 2017 | 64.01% |
| Jun 30, 2017 | -68.47% |
| Sep 30, 2016 | -54.62% |